« Zurück
Home /
Polyinosinic-polycytidylic acid

Polyinosinic-polycytidylic acid

ArtNr	HY-107202-50mg
Hersteller	MedChem Express
CAS-Nr.	24939-03-5
Menge	50 mg
Quantity options	100 mg 10 mg 25 mg 50 mg 5 mg
Kategorie	Inhibitors & Compound Libraries Small Molecules
Typ	Molecules
Specific against	other
Formula	(C10H13N4O8P)x.(C9H14N3O8P)x
Citations	Autophagy. 2024 May 18. Biochem Biophys Res Commun. 2024 Feb 15, 149661. bioRxiv. 2024 Dec 8:2024.12.07.627371. bioRxiv. 2024 September 23. Cancer Immunol Res. 2024 Jul 11. Cancer Med. 2023 Jun 7. Chem Biol Drug Des. 2023 Nov;102(5):1110-1120. Chem Eng J. 2021 Aug 15;418:129392. Clin Cosmet Investig Dermatol. 2024 May 14:17:1093-1105. Clin Transl Med. 2024 Sep;14(9):e70027. Curr Microbiol. 2024 Aug 6;81(9):296. FASEB J. 2024 Mar 31. Res Sq. 2024 Nov 14. SSRN. 2023 Apr 29. Vet Res. 2024 Sep 27;55(1):115. Virol Sin. 2023 Aug 24;S1995-820X(23)00104-9. Virol Sin. 2023 May 2;S1995-820X(23)00048-2. Adv Funct Mater. 29 August 2022. Liver Int. 2022 Oct 17. Mol Ther Oncolytics. 25 August 2022. Phytomedicine. 2021, 153495. SSRN. 2021 Apr 26. [1]Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732-738. [2]Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 2002;293(5):1364-1369. [3]Cheng Y, Xu F. Anticancer function of polyinosinic-polycytidylic acid [J]. Cancer biology & therapy, 2010, 10(12): 1219-1223. [4]Deleidi M, Hallett P J, Koprich J B, et al. The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration [J]. Journal of Neuroscience, 2010, 30(48): 16091-16101. [5]Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer [J]. The Journal of Immunology, 2012, 188(11): 5357-5364. [6]Rezaee F, Meednu N, Emo J A, et al. Polyinosinic: polycytidylic acid induces protein kinase D–dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells [J]. Journal of Allergy and Clinical Immunology, 2011, 128(6): 1216-1224. e11. [7]Wang P F, Fang H, Chen J, et al. Polyinosinic-polycytidylic acid has therapeutic effects against cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via TLR3 [J]. The Journal of Immunology, 2014, 192(10): 4783-4794.
Smiles	O[C@H]1[C@@H](O[C@H](COP(O)(O)=O)[C@H]1O)N2C3=C(C(NC=N3)=O)N=C2.O[C@H]4[C@H](N5C(N=C(N)C=C5)=O)O[C@H](COP(O)(O)=O)[C@H]4O.[x].[x]
ECLASS 10.1	32169090
ECLASS 11.0	32169090
UNSPSC	12000000
Alias	Poly(I:C)
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Targets	Bcl-2 Family; HSP; Interleukin Related; PKD; Toll-like Receptor (TLR)
Shipping Temperature	Blue Ice
Storage Conditions	-20°C, 3 years (Powder)
Product Description	Polyinosinic-polycytidylic acid (Poly(I:C)) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis[1][2].
Manufacturer - Research Area	Cancer; Infection; Inflammation/Immunology
Solubility	H2O : 50 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease
Isoform	Bax; Bcl-2; HSP70; IL-13; IL-17
Clinical information	No Development Reported

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-107202-50mg-safety-datasheet.pdf